

A large, stylized molecular structure graphic composed of white and light blue lines and dots, resembling a network or a chemical lattice, is positioned on the left side of the page, extending from the top left towards the bottom right.

iQ UEGO
Indústria Química do Estado de Goiás S/A

INNOVATION IN PUBLIC HEALTH

GOVERNO DE
GOIÁS

History



INNOVATION IN PUBLIC HEALTH

Founded over 60 years ago, IQUEGO is the only public laboratory in the Central-West region of Brazil, occupying an industrial park of 40,615.22 m², with 15,024.29 m² of built area. The institution stands out for its robust infrastructure and its vital role in providing essential medicines for the Unified Health System (SUS).

From a new perspective, IQUEGO seeks to diversify its portfolio through partnerships with universities, research centers, and other laboratories, fostering the development of new products and technology transfer. With a forward-looking vision, IQUEGO aims not only to be a leader in the health industry complex but also to establish itself as a reference Technology Institute in Brazil, even seeking international partnerships to advance in the pharmaceutical and health product manufacturing industry.

Mission

To produce, market, and distribute quality medicines and health products at competitive prices, as well as conduct scientific research for the development of new medicines and pharmaceutical products, meeting the programs and demands of the country's public health system.

Vision

To be a national reference official laboratory in technological development, innovation, research, and production of medicines and health products.

Values

- ◊ Overcoming and Trust
- ◊ Innovation with Focus on Safety Assurance
- ◊ Ethics and Transparency
- ◊ Efficacy and Quality in Production and Marketing
- ◊ Respect for Life, People, and the Environment

Product Portfolio

IQUEGO stands out in the production of a wide variety of essential products for public health, significantly contributing to the Unified Health System (SUS). Our diverse catalog reflects the commitment to providing accessible and effective treatments for various medical conditions. Check out some of the products available and in development:



CANNABIDIOL (CBD):

Prescribed for a variety of conditions, such as chronic pain, inflammations, epilepsy, among others. CBD offers an important therapeutic option for patients with specific needs.



BLOOD GLUCOSE MONITORING SYSTEM:

Essential for both home and professional blood glucose monitoring, our Okmeter Match II and Glucoleader glucometers ensure privacy and accuracy without the need for coding chips.



INSULIN PEN NEEDLES:

An essential item for patients who rely on insulin for controlling diabetes, ensuring safe and effective administration of the medication.



REPELLENT :

Important for protection against bites from mosquitoes - diseases transmitter - such as Dengue, Zika, Chikungunya, and Malaria. It ensures the safety and well-being of the population.



QUETIAPINE:

Antipsychotic medication used for the treatment of schizophrenia, attenuating severe psychotic symptoms and improving patients' quality of life.

RIVAROXABAN

Orally-administered anticoagulant. It is crucial in the treatment of cardiovascular diseases, preventing the formation of blood clots and reducing the risk of severe complications.

GABAPENTIN :

Anticonvulsant medication essential in controlling epileptic seizures. It ensures stability and safety to epilepsy patients.

SOFOSBUVIR AND DACLASTASVIR:

Essential Antivirals in treating chronic hepatitis C. It helps to eliminate the virus and prevent severe liver damage.

LEVETIRACETAM:

Another anticonvulsant used to control focal seizures in epilepsy patients. It significantly improves the quality of life for those patients.




A close-up, high-angle photograph of a microscope, showing the objective lenses and eyepiece, set against a dark background with blue highlights. The image is partially cut off by the top-right corner of the page.

Innovation & New Products

IQUEGO is firmly committed to ongoing innovation and research, aiming to continuously expand its product portfolio to meet the dynamic needs of public health. Our strategic focus includes the development of new products through technology transfer partnerships with renowned institutions, such as universities and research centers, both in Brazil and internationally.

We are currently involved in various Research and Development (R&D) projects that explore new formulations and technologies to improve therapeutic efficacy and treatment accessibility. These efforts are directed towards critical areas such as diabetes, epilepsy, hepatitis C, and other significant health conditions. In addition to innovating in medicines, we are also expanding our line of medical devices, including advanced glucose monitoring systems and other products that contribute to patient well-being and quality of life.

As we move forward, we will continue to invest in R&D initiatives that not only address current needs but also anticipate future demands of Brazilian public health. This approach reaffirms our commitment to being a center of excellence in technology and research, significantly contributing to the ongoing advancement of health in the country.

Decorative geometric shapes in shades of blue and cyan, located in the bottom-left corner of the page.

Target Audience and Market

IQUEGO, a leading entity in the public health sector in Brazil, serves public hospitals, state and municipal health departments, as well as the Unified Health System (SUS), the Ministry of Health, and various philanthropic organizations nationwide. Our mission is to distribute pharmaceuticals and health products at reduced costs, thereby advancing public health and mitigating regional disparities in access to essential treatments.

Beyond national markets, we are seeking to expand our operations globally through international partnerships for technology transfer. These collaborations strengthen our portfolio and increase our capacity to offer innovative and accessible solutions in health. All our products are developed with a focus on quality, safety, and therapeutic efficacy, complying with the strictest regulatory requirements.

Internal Regulation of Business Opportunities (RICON - Brazilian Acronym):

IQUEGO has instituted the Internal Regulations for Business Opportunities (RICON) to regulate the evaluation and conclusion of legal transactions, as provided for in article 28, § 3, item II of Federal Law No.13,303/2016.



Ministry of Health



State and Municipal Health Departments

and other institutions providing or managing public, free, and/or philanthropic health services



Research and Development (R&D) Companies



Research Institutes



Private Companies

interested in partnerships in the area of public health

Strategic Location and Negotiation Benefits

IQUEGO is strategically located in Goiânia, Goiás State, Brazil. This central location is crucial for our operations, enabling easy access and efficient distribution of our products to all regions of the country. Our strategic location in the heart of Brazil allows us to quickly address the demands of the domestic market and respond swiftly to any emerging needs from our clients, including public hospitals, State health departments, and the Federal Government.



The geographic location of IQUEGO offers several competitive advantages for international negotiations. We are close to major transportation and logistics routes, facilitating transport of our products to global markets by land, air and sea. Additionally, Goiânia is strategically positioned for international collaborations, offering a favorable environment for technology transfer partnerships and joint development of new products with global partners.

The Chemical and Pharmaceutical Industry Growth

Posição País

- 1 China
- 2 Índia
- 3 Estados Unidos
- 4 Indonésia
- 5 Brasil
- 6 Paquistão
- 7 Nigéria
- 8 Bangladesh
- 9 Rússia
- 10 Japão
- 11 México
- 12 Etiópia
- 13 Filipinas
- 14 Egípto
- 15 Vietnã
- 16 Congo-Kinshasa
- 17 Irã
- 18 Turquia
- 19 Alemanha
- 20 Tailândia


População



Fonte: CIA World Factbook

Potential of the Pharmaceutical Market in Brazil

Brazil ranks 5th among the most populous countries in the world. It currently has around 207 million inhabitants. This makes Brazil highly attractive due to its consumption potential.



Age of the Brazilian Population

The age pyramid is changing in Brazil. The elderly part of the Brazilian population, such as those over 60 years old, increased by around 15% in 2022, according to data from IBGE. With a growing population that ages every year, contrasting this demographic information, we can conclude Brazil will have a sharp growth in the demand for medicines and health services. At this level, the pharmaceutical industries, distributors and retailers will make a lot of money in the Brazilian market.

Appointments per month

All this movement in the pharmaceutical market in Brazil represents approximately 2% of the global market, placing Brazil in 7th place in the world ranking of the 20 largest economies. If we analyze only Latin America, Brazil is the leader in the pharmaceutical market, positioning itself ahead of countries such as Mexico, Colombia and Argentina.



Simplified Acquisition Process

IQUEGO stands out for its efficiency and flexibility in selling medicines and health products to public agencies, following the guidelines established by Federal Law 14,133/2021, art. 75, IX. We offer several acquisition methods to meet the needs of our customers:

Who can purchase from IQUEGO?

- Federal Government.
- States and Municipalities.
- Public Health Consortiums.
- Non-profit entities of the Unified Health System (SUS).

Bidding Exemption Contract:

- Preferably for 6 or 12 months
- Deadline of up to 30 days for payment after issuance of the invoice.
- Immediate delivery of available products.

Cash:

- Signed by the secretary.
- Deadline of up to 30 days for payment.
- Immediate release of available products.


Forms of Acquisition:

- Supply authorization.
- Payment according to the amount of the invoice sent.

Bidding Exemption:

- Legal basis: art. 75, section IX of Law No. 14,133/2021.
- Allows direct acquisition of goods and services from government agencies which are part of the Public Administration, as long price is compatible With the market.



 **+55 (62) 3030-1165**

SAC: 0800 943 2928

 **www.goias.gov.br/iuego/**

 **@iuegooficial**

 **Avenida Anhanguera, 12527
Qd 56 It 1, Goiânia - Goiás
CEP: 74453-390**



Portfólio



Site

